Next Article in Journal
Heightened TLR7/9-Induced IL-10 and CXCL13 Production with Dysregulated NF-ҝB Activation in CD11chiCD11b+ Dendritic Cells in NZB/W F1 Mice
Next Article in Special Issue
Micronutrient Depletion in Heart Failure: Common, Clinically Relevant and Treatable
Previous Article in Journal
Identification of Functional and Druggable Sites in Aspergillus fumigatus Essential Phosphatases by Virtual Screening
Previous Article in Special Issue
Ginseng Berry Extract Rich in Phenolic Compounds Attenuates Oxidative Stress but not Cardiac Remodeling post Myocardial Infarction
Review

Klotho: A Major Shareholder in Vascular Aging Enterprises

1
Division of Nephrology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
2
MGH Renal Associates, 165 Cambridge Street, Suite 302, Boston, MA 02114, USA
3
Renal Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02114, USA
4
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (UCSF), 1450 3rd St, San Francisco, CA 94158, USA
5
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(18), 4637; https://doi.org/10.3390/ijms20184637
Received: 6 August 2019 / Revised: 11 September 2019 / Accepted: 13 September 2019 / Published: 19 September 2019
(This article belongs to the Special Issue Nutrition and Cardiovascular Health)
Accelerated vascular aging is a condition that occurs as a complication of several highly prevalent inflammatory conditions such as chronic kidney disease, cancer, HIV infection and diabetes. Age-associated vascular alterations underlie a continuum of expression toward clinically overt cardiovascular disease. This has contributed to the striking epidemiologic transition whereby such noncommunicable diseases have taken center stage as modern-day global epidemics and public health problems. The identification of α-Klotho, a remarkable protein that confers powerful anti-aging properties has stimulated significant interest. In fact, emerging data have provided fundamental rationale for Klotho-based therapeutic intervention for vascular diseases and multiple other potential indications. However, the application of such discoveries in Klotho research remains fragmented due to significant gaps in our molecular understanding of Klotho biology, as well as hurdles in clinical research and experimental barriers that must first be overcome. These advances will be critical to establish the scientific platform from which future Klotho-based interventional trials and therapeutic enterprises can be successfully launched. View Full-Text
Keywords: vascular aging; vascular calcification; arteriosclerosis; Klotho; chronic kidney disease (CKD), cancer; diabetes vascular aging; vascular calcification; arteriosclerosis; Klotho; chronic kidney disease (CKD), cancer; diabetes
Show Figures

Figure 1

MDPI and ACS Style

Lim, K.; Halim, A.; Lu, T.-s.; Ashworth, A.; Chong, I. Klotho: A Major Shareholder in Vascular Aging Enterprises. Int. J. Mol. Sci. 2019, 20, 4637. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms20184637

AMA Style

Lim K, Halim A, Lu T-s, Ashworth A, Chong I. Klotho: A Major Shareholder in Vascular Aging Enterprises. International Journal of Molecular Sciences. 2019; 20(18):4637. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms20184637

Chicago/Turabian Style

Lim, Kenneth, Arvin Halim, Tzong-shi Lu, Alan Ashworth, and Irene Chong. 2019. "Klotho: A Major Shareholder in Vascular Aging Enterprises" International Journal of Molecular Sciences 20, no. 18: 4637. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms20184637

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop